SCHEMBL20161154

SCHEMBL20161154

FC(F)(F)c1n[nH]c(-c2nn(Cc3ccccc3)c3ncccc23)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.50
ESR1 P03372 1/20 0.38
PDE5A O76074 9/20 0.38
HSD11B1 P28845 1/20 0.36
NR1H2 P55055 1/20 0.36
NR1H3 Q13133 1/20 0.36
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
PPARG P37231 1/20 0.35
NCOA2 Q15596 1/20 0.35
NCOA1 Q15788 1/20 0.35
NCOA3 Q9Y6Q9 1/20 0.35
ALDH1A1 P00352 1/20 0.35
KDM4E B2RXH2 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20140339 0.92 L3MBTL1 (0.40) L3MBTL1PDE5ANR1H2NR1H3CYP1A2
SCHEMBL20139619 0.91 L3MBTL1 (0.45) L3MBTL1PDE5ACYP1A2CYP3A4CYP2C19
SCHEMBL20140418 0.89 L3MBTL1 (0.38) L3MBTL1PDE5AKDM4ECYP1A2CYP3A4
SCHEMBL20140459 0.89 MAPT (0.43) L3MBTL1PDE5AMEN1KMT2AALDH1A1
SCHEMBL20161279 0.89 L3MBTL1 (0.37) L3MBTL1PDE5AMEN1KMT2A
SCHEMBL20148909 0.88 L3MBTL1 (0.41) L3MBTL1PDE5A
SCHEMBL20148908 0.86 PDE5A (0.51) PDE5A
SCHEMBL20139738 0.86 GUCY1A1 (0.35) L3MBTL1PDE5A
SCHEMBL20140449 0.85 PDE5A (0.40) PDE5A
SCHEMBL20161254 0.85 PDE5A (0.40) PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435080-B2 sGC stimulators TISENTO THERAPEUTICS INC. (US) 2025-10-07 US disclosed
US-20220017515-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-20 US disclosed
US-20220017515-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-20 US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 US disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 US disclosed
WO-2018111795-A2 USE OF SGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-06-21 WO disclosed
WO-2018089330-A2 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071318-A1 SGC STIMULATORS GUCY1A2, GMPS, PDE2A L3MBTL1 4698/4885ESR1 4348/4885PDE5A 12/4885
US-20220017515-A1 sGC STIMULATORS GUCY1A2, PRKG1, PDE2A L3MBTL1 4695/4885ESR1 4345/4885PDE5A 12/4885
US-12435080-B2 sGC stimulators GUCY1A2, PRKG1, PDE2A L3MBTL1 4695/4885ESR1 4345/4885PDE5A 12/4885
US-11180493-B2 SGC stimulators GUCY1A2, GMPS, PDE2A L3MBTL1 4698/4885ESR1 4348/4885PDE5A 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.